These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25533324)

  • 1. [Chances and risks of blood-based molecular pathological analysis of circulating tumor cells (CTC) and cell-free DNA (cfDNA) in personalized cancer therapy: positional paper from the study group on liquid biopsy of the working group for molecular pathology in the German Society of Pathology (DGP)].
    Dahl E; Jung A; Fassunke J; Hummel M; Penzel R; Dietmaier W; Laßmann S
    Pathologe; 2015 Feb; 36(1):92-7. PubMed ID: 25533324
    [No Abstract]   [Full Text] [Related]  

  • 2. Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.
    Donovan MJ; Cordon-Cardo C
    Mol Diagn Ther; 2017 Apr; 21(2):115-123. PubMed ID: 28000172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor cells in breast cancer: applications in personalized medicine.
    Lee JS; Magbanua MJM; Park JW
    Breast Cancer Res Treat; 2016 Dec; 160(3):411-424. PubMed ID: 27761678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
    Alix-Panabières C; Pantel K
    Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Liquid biopsy analysis using cell-free DNA (cfDNA): Opportunities and limitations].
    Dahl E; Kloten V
    Pathologe; 2015 Nov; 36(6):572-8. PubMed ID: 26395890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid biopsy: a step forward towards precision medicine in urologic malignancies.
    Di Meo A; Bartlett J; Cheng Y; Pasic MD; Yousef GM
    Mol Cancer; 2017 Apr; 16(1):80. PubMed ID: 28410618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy.
    Schlange T; Pantel K
    Pharmacogenomics; 2016 Feb; 17(3):183-6. PubMed ID: 26799583
    [No Abstract]   [Full Text] [Related]  

  • 8. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.
    Ignatiadis M; Lee M; Jeffrey SS
    Clin Cancer Res; 2015 Nov; 21(21):4786-800. PubMed ID: 26527805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis.
    Court CM; Ankeny JS; Hou S; Tseng HR; Tomlinson JS
    Expert Rev Mol Diagn; 2015; 15(11):1491-504. PubMed ID: 26390158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.
    Vendrell JA; Mau-Them FT; Béganton B; Godreuil S; Coopman P; Solassol J
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor cells in patients with lung cancer: developments and applications for precision medicine.
    Tong B; Wang M
    Future Oncol; 2019 Jul; 15(21):2531-2542. PubMed ID: 31339062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
    Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
    Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pathway to clinical use of a cancer biomarker.
    Henry NL
    Scand J Clin Lab Invest Suppl; 2016; 245():S17-21. PubMed ID: 27410238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging concepts in liquid biopsies.
    Perakis S; Speicher MR
    BMC Med; 2017 Apr; 15(1):75. PubMed ID: 28381299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using CTCs for pharmacogenomic analysis.
    Hart CD; Galardi F; Pestrin M; De Luca F; Risi E; Di Leo A
    Pharmacol Res; 2016 Apr; 106():92-100. PubMed ID: 26921662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid Biopsy in Primary Brain Tumors: Looking for Stardust!
    Fontanilles M; Duran-Peña A; Idbaih A
    Curr Neurol Neurosci Rep; 2018 Mar; 18(3):13. PubMed ID: 29520561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?
    Zhang W; Xia W; Lv Z; Ni C; Xin Y; Yang L
    Cell Physiol Biochem; 2017; 41(2):755-768. PubMed ID: 28214887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid Biopsy: From Basic Research to Clinical Practice.
    Macías M; Alegre E; Díaz-Lagares A; Patiño A; Pérez-Gracia JL; Sanmamed M; López-López R; Varo N; González A
    Adv Clin Chem; 2018; 83():73-119. PubMed ID: 29304904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.